LDN Benefits: What Research Shows About Reducing Inflammation Markers

Recent studies on LDN benefits reveal promising results for reducing inflammation. Research shows that patients with fibromyalgia who took low-dose naltrexone at 4.5 mg daily saw pain reduced by 15% and overall symptoms by 18%. 57% of participants experienced considerable pain reduction during treatment. Studies showed that low dose naltrexone benefits extend to reducing 17 different inflammatory markers. These include interleukin-6, TNF-alpha, and C-reactive protein. We’ll get into the research evidence behind these inflammation reductions and how LDN works in the body. We’ll also cover its applications for conditions like fibromyalgia, Crohn’s disease, and rheumatoid arthritis.

What is Low Dose Naltrexone (LDN)

Understanding naltrexone and its origins

Researchers synthesized naltrexone in 1963 as an orally active competitive opioid receptor antagonist ^[1]. Endo Laboratories developed it as an alternative to existing opioid antagonists and found it structurally and functionally as with naloxone but with greater oral bioavailability and a longer biologic half-life ^[1].

The FDA approved naltrexone hydrochloride in 1984 to treat opioid addiction ^[1]. Congress had passed legislation that wanted to develop non-addictive treatments for heroin addiction, which drove interest in naltrexone as a safe alternative to methadone. The medication proved effective at blocking the effects of opioids without producing major central nervous system side effects.

Dr. Bernard Bihari’s work in the mid-1980s marked a turning point. He treated HIV patients in New York and noticed positive effects when weaning patients off standard naltrexone doses ^[1]. His observation that many patients with autoimmune diseases had low endorphin levels led him to experiment with much smaller doses. Dr. Bihari found that administering lower doses at night, when the body produces peak endorphin levels between 2:00am and 4:00am naturally, could boost endorphin production by 200 to 300% ^[2]. The first published human trial came in 2007 by Dr. Jill Smith and focused on Crohn’s disease ^[1].

The difference between standard and low doses

The typical daily dosage to treat opioid addiction ranges from 50.0 to 100.0 mg daily, with 50.0-mg tablets available commercially ^[1]. LDN refers to daily dosages that are about one-tenth of the typical opioid addiction treatment dosage ^[1].

Most published research uses a daily dosage of 4.5 mg ^[1]. Doses in clinical practice range from 0.001mg to 16mg ^[1]. Standard doses of naltrexone block the effects of both endogenous opioids (found in endorphins) and pharmaceutical opioids. This complete blockage at higher doses made it useful to treat addiction but also blocked the positive effects of the body’s natural endorphins.

Low dose naltrexone binds to endorphin receptors for about 1 to 1.5 hours, with the blockade lasting about 4 to 6 hours ^[1]. This brief, temporary blockage creates what researchers call a paradoxical effect. Naltrexone exhibits paradoxical properties at the low dosage level, including analgesia and anti-inflammatory actions, which have not been reported at larger dosages ^[1].

The mechanism works because the body interprets this brief blockade as a shortage of endorphins. The body ramps up production of naturally occurring opioids to compensate. This rebound effect increases both endorphins, including opioid growth factor (OGF), and the production of OGF receptors ^[1]. Endorphins are natural peptides produced in many cells that regulate cell growth, including immune cells ^[1]. Patients with autoimmune diseases often have low levels of these immunomodulatory compounds.

How LDN is different from conventional anti-inflammatories

Naltrexone exerts its effects on humans via at least two distinct receptor mechanisms ^[1]. Beyond the antagonist effect on mu-opioid and other opioid receptors, naltrexone has an antagonist effect on non-opioid receptors at the same time ^[1]. These non-opioid receptors, specifically Toll-like receptor 4 (TLR4), are found on macrophages such as microglia ^[1].

LDN is thought to exert its anti-inflammatory effects via this non-opioid antagonist path ^[1]. This mechanism separates LDN from conventional anti-inflammatory medications that work by blocking prostaglandin synthesis or reducing immune cell activity through different pathways.

The anti-inflammatory effect of opioid antagonists may also extend to the periphery, as evidenced by suppressed TNF-alpha, IL-6, MCP-1, and other inflammatory agents in peripheral macrophages ^[1]. A range of symptoms and medical outcomes could share the pathophysiological mechanism of central inflammation, given the wide variety of inflammatory factors produced by activated microglia (such as proinflammatory cytokines, substance P, nitric oxide, and excitatory amino acids) ^[1].

LDN is inexpensive and patients tolerate it well as a daily oral therapy ^[1]. Despite the promise of efficacy, the use of LDN for chronic disorders is still experimental ^[1]. The approach is used to both increase the efficacy of opioid analgesia therapy and reduce some adverse side effects ^[1].

How LDN Reduces Inflammation in the Body

The blocking action of naltrexone on inflammation pathways

Naltrexone, particularly at low doses, works by blocking certain inflammation triggers in the body. It targets a specific receptor called TLR4, which plays a key role in the body’s inflammatory response during conditions like pain, infection, and autoimmune diseases.

When used at low doses, naltrexone:

• Prevents brain immune cells (microglia) from switching into an inflammatory state

• Reduces the production of inflammatory substances that can cause pain and tissue damage

• Creates a molecular “interference” that disrupts inflammatory signaling pathways

Current research has limitations. Published studies involve small numbers of participants, with few studies being repeated by other researchers. Larger clinical trials are needed to confirm LDN’s effectiveness for pain reduction. The overall evidence remains limited due to the small number of published studies and their small size. The wide differences in how studies were designed, how LDN was administered, and how results were measured prevented researchers from combining data across studies for stronger conclusions.

Potential treatment combinations:

• Oxytrex (LDN combined with oxycodone) showed promise for lower back pain

• Early studies suggest LDN combined with l-THP might work better for addiction treatment

• Researchers are exploring LDN as an additional treatment for depression with inflammation

Finding the right dose:

• Studies show that effective doses vary from patient to patient for chronic pain

• The best dose depends on the individual, not on following a standard protocol

• Proper dosing studies are needed to determine the effective range and identify individual optimal amounts

• Understanding dose specificity helps doctors find the minimum effective dose for each patient instead of using one-size-fits-all doses

In summary:
Research shows LDN reduces 17 different inflammatory markers, especially TNF-alpha, IL-6, and C-reactive protein. It works by blocking TLR4 and modulating microglia, offering a different approach than typical anti-inflammatory medications. At 4.5mg daily, LDN has shown improvements in pain and symptoms for conditions like fibromyalgia, Crohn’s disease, and rheumatoid arthritis. Most patients handle it well with few side effects. However, current research is based on small studies. Talk with your healthcare provider about whether LDN might be right for your condition. Larger clinical trials will help establish clear treatment guidelines and identify who benefits most from this therapy.

References

[1] – https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/low-dose-naltrexone-usage-in-ms
[2] – https://www.harborcompounding.com/brief-discovery-of-low-dose-naltrexone
[3] – https://www.medicalnewstoday.com/articles/ldn-for-rheumatoid-arthritis
[4] – https://www.assaygenie.com/blog/key-functions-of-microglial-cells-in-cns-health-immunity-neuroinflammation/?srsltid=AfmBOor5XbDcwTBag_Ld5P8Xk9PiBZHdzx_4PFwg8Gtj5PgOFPC7WfBo
[5] – https://www.nature.com/articles/s41392-023-01588-0
[6] – https://pmc.ncbi.nlm.nih.gov/articles/PMC6700752/
[7] – https://columbiapain.org/exploring-the-potential-of-low-dose-naltrexone-in-modulating-toll-like-receptor-activity-for-personalized-nociplastic-pain-treatment/
[8] – https://pmc.ncbi.nlm.nih.gov/articles/PMC10201089/
[9] – https://www.sciencedirect.com/science/article/abs/pii/S0898656825002815
[10] – https://www.psu.edu/news/medicine/story/use-naltrexone-reduces-inflammation-crohns-patients
[11] – https://www.jucm.com/management-of-patients-on-low-dose-naltrexone-a-clinical-review-for-urgent-care-providers/
[12] – https://cancerchoices.org/therapy/low-dose-naltrexone/safety/
[13] – https://www.umventures.org/technologies/1-thpldn-low-dose-naltrexone-combination-medication-substance-dependence-disorder
[14] – https://link.springer.com/article/10.1186/s13063-022-06738-3
[15] – https://pmc.ncbi.nlm.nih.gov/articles/PMC5845217/
[16] – https://www.gastrojournal.org/article/S0016-5085(21)04033-6/fulltext
[17] – https://pmc.ncbi.nlm.nih.gov/articles/PMC5433405/
[18] – https://www.clevelandclinicmeded.com/showcase/EKCC138/docs/1430_Hill_Dose.pdf
[19] – https://asra.com/news-publications/asra-newsletter/newsletter-item/asra-news/2023/11/06/low-dose-naltrexone-is-it-really-worth-the-hype
[20] – https://pmc.ncbi.nlm.nih.gov/articles/PMC10964028/
[21] – https://www.ncbi.nlm.nih.gov/books/NBK534811/
[22] – https://www.dvcstem.com/post/side-effects-of-low-dose-naltrexone
[23] – https://pmc.ncbi.nlm.nih.gov/articles/PMC12017383/
[24] – https://www.sciencedirect.com/science/article/pii/S2405844023028451
[25] – https://pmc.ncbi.nlm.nih.gov/articles/PMC3962576/
[26] – https://pmc.ncbi.nlm.nih.gov/articles/PMC8591911/
[27] – https://pmc.ncbi.nlm.nih.gov/articles/PMC10039621/
[28] – https://www.mdpi.com/2227-9059/11/6/1620
[29] – https://www.centerforpain.net/low-dose-naltrexone